Potent Neutralizing Antibodies Elicited By Rbd-Fc-Based Covid-19 Vaccine Candidate Adjuvanted By The Th2-Skewing Inkt Cell Agonist

The development of a safe and effective COVID-19 vaccine is of paramount importance to terminate the current pandemic. An adjuvant is crucial for improving the efficacy of the subunit COVID19 vaccine. alpha-Galactosylceramide (alpha GC) is a classical iNKT cell agonist which causes the rapid production of Th1- and Th2-associated cytokines; we, therefore, expect that the Th1- or Th2-skewing analogues of alpha GC can better enhance the immunogenicity of the receptor-binding domain in the spike protein of SARS-CoV-2 fused with the Fc region of human IgG (RBD-Fc). Herein, we developed a universal synthetic route to the Th1-biasing (alpha-C-GC) and Th2-biasing (OCH and C20:2) analogues. Immunization of mice demonstrated that alpha GC-adjuvanted RBD-Fc elicited a more potent humoral response than that observed with Alum and enabled the sparing of antigens. Remarkably, at a low dose of the RBD-Fc protein (2 mu g), the Th2-biasing agonist C20:2 induced a significantly higher titer of the neutralizing antibody than that of Alum.